Friday, October 16, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· January 16, 2026

Stock market today: Dow, S&P 500, Nasdaq steady as Trump wavers on Kevin Hassett as next Fed chair

View original at finance.yahoo.com
Stock market today: Dow, S&P 500, Nasdaq steady as Trump wavers on Kevin Hassett as next Fed chair US stocks pared gains on Friday as uncertainty over the next Fed chair weighed on markets, while strong bank earnings and ongoing geopolitical tensions capped a volatile week…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Moving Hassett to Fed would mean losing him from current role

    80% confidence
  • Small-cap earnings are just beginning to take off after two-year earnings recession

    80% confidence
  • Affordability conditions taking toll on lower and mid-range housing sectors

    80% confidence
  • Lower interest rates help small caps as 40% of Russell 2000 debt is variable

    80% confidence
  • Trump wants to keep Kevin Hassett as NEC director rather than naming him Fed Chair

    80% confidence
  • Tehran's crackdown on protesters is easing

    80% confidence
  • Small caps can outperform for over a decade when they begin outperforming

    80% confidence
  • Fed sees risks to job market and should be ready to cut rates

    80% confidence
  • ASML shares could surge 70% in bull case

    80% confidence
  • May use tariffs in pursuit of Greenland acquisition

    80% confidence
  • Investors pondering what would push 10-year yields to 4.25% or 4.05%

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com